As mentioned above, there are currently several clinical trials ongoing in which the combination of HDAC inhibition and immunotherapy is tested as treatment of solid tumors (Supplementary Table S4); based on the presented data, MCC should be one of these cancers. This evidence concerns the gene HDAC9 and cancer.